Zika virus (ZIKV) is an illness people can get from mosquitoes. The infection is generally mild with symptoms that include a fever, rash, red eyes, and joint pain, though most of those infected have no symptoms. Preventing ZIKV is important because if a pregnant person is infected with ZIKV, it can cause birth defects in their unborn child. The goals of this study are to find out if people who have already been infected with one type of ZIKV can get infected with ZIKV a second time, and to test the ability of the TV003 dengue vaccine to prevent people from getting infected with the ZIKV-SJRP challenge virus.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Incidence, magnitude, and duration of infectious ZIKV-SJRP/2016-184 recovered from serum following administration of ZIKV-SJRP/2016-184 in subjects who received TV003
Timeframe: Through 180 days post challenge
Incidence, magnitude, and duration of infectious ZIKV-SJRP/2016-184 recovered from serum following administration of ZIKV-SJRP/2016-184 in ZIKV-exposed subjects
Timeframe: Through 180 days post challenge
Proportion of subjects who received TV003 who develop clinical signs/symptoms of Zika infection
Timeframe: Through 180 days post challenge
Proportion of subjects who were previously infected with ZIKV who develop clinical signs/symptoms of Zika infection
Timeframe: Through 180 days post challenge
Frequency of immediate, systemic, and local adverse events (AEs) following vaccination with TV003
Timeframe: Through 28 days post vaccination
Frequency of immediate, systemic, and local AEs following inoculation with ZIKV-SJRP/2016-184
Timeframe: Through 28 days post challenge